|
|
Lyon, France – 21 décembre 2022 – 18h00 CET – Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques et pionnière dans le développement de candidats médicaments agissant sur l'interaction entre neurones et cellules gliales, publie aujourd'hui son agenda financier pour l'année... Lire le communiqué |
|
| |
|
| |
|
|
Lyon, France – 21 December 2022 – 6:00pm CET Theranexus, an innovative biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its financial communication agenda for 2023. Each publication will be released after Euronext market... Lire le communiqué |
|
| |
|
| |
|
|
Lyon, France – 20 décembre 2022 – 18h00 CET Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques et pionnière dans le développement de candidats médicaments agissant sur l'interaction entre neurones et cellules gliales, annonce aujourd'hui sa participation à la 41ème... Lire le communiqué |
|
| |
|
| |
|
|
Lyon, France – 20 December 2022 – 6:00pm CET Theranexus, an innovative biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announced today that it will participate in the 41st Annual J.P. Morgan Healthcare Conference, bringing together all the... Lire le communiqué |
|
| |
|
| |
|
|
Lyon, France – Austin, Texas, EtatsUnis – 2 novembre 2022 – 18h00 CET Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques et pionnière dans le développement de candidats médicaments agissant sur l'interaction entre neurones et cellules gliales et la Fondation Beyond Batten Disease BBDF, annoncent... Lire le communiqué |
|
| |
|
| |
|
|
Lyon, France – Austin, Texas, United States – 2 November 2022 – 6pm CET Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, and the Beyond Batten Disease Foundation BBDF, have today announced the presentation of research,... Lire le communiqué |
|
| |
|
| |
|
|
Lyon, Paris, France – 20th October 2022 – 6 pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, and Inserm Transfert, the technology transfer office and private subsidiary of the French National Institute of Health and... Lire le communiqué |
|
| |
|
| |
